​

BridgeBio Pharma (BBIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BBIO Stock Forecast

BridgeBio Pharma (BBIO) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $88.80, with a high of $100.00 and a low of $69.00. This represents a 14.12% increase from the last price of $77.81.

$20 $36 $52 $68 $84 $100 High: $100 Avg: $88.8 Low: $69 Last Closed Price: $77.81

BBIO Stock Rating

BridgeBio Pharma stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 24 Buy (96.00%), 1 Hold (4.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 1 24 Strong Sell Sell Hold Buy Strong Buy

BBIO Price Target Upside V Benchmarks

TypeNameUpside
StockBridgeBio Pharma14.12%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts31215
Avg Price Target$90.00$87.33$83.87
Last Closing Price$77.81$77.81$77.81
Upside/Downside15.67%12.23%7.79%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 263151--19
Dec, 253141--18
Nov, 254141--19
Oct, 254141--19
Sep, 254151-121
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 20, 2026Tiago FauthWells Fargo$88.00$76.2615.39%13.10%
Jan 08, 2026Truist Financial$86.00$74.2715.79%10.53%
Jan 06, 2026Morgan Stanley$96.00$73.4230.75%23.38%
Dec 15, 2025Leerink Partners$86.00$74.5915.30%10.53%
Dec 11, 2025Bernstein$94.00$72.7029.30%20.81%
Oct 30, 2025Truist Financial$80.00$63.8825.23%2.81%
Oct 30, 2025Oppenheimer$81.00$64.3925.80%4.10%
Oct 30, 2025Piper Sandler$98.00$66.6247.10%25.95%
Oct 30, 2025Paul ChoiGoldman Sachs$100.00$66.6250.11%28.52%
Oct 29, 2025H.C. Wainwright$90.00$65.7336.92%15.67%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 20, 2026Wells FargoOverweightOverweighthold
Jan 12, 2026Cowen & Co.BuyBuyhold
Jan 06, 2026Morgan StanleyOverweightinitialise
Dec 11, 2025BernsteinOutperforminitialise
Oct 30, 2025Cowen & Co.PositivePositivehold
Oct 30, 2025Cowen & Co.BuyBuyhold
Oct 30, 2025OppenheimerOutperformOutperformhold
Oct 30, 2025Piper SandlerOverweightOverweighthold
Oct 30, 2025Goldman SachsBuyBuyhold
Oct 28, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.43$-3.35$-3.95$-2.88----
Avg Forecast$-3.70$-3.13$-3.76$-2.52$-3.55$-2.51$-0.57$1.91
High Forecast$-1.53$-1.18$-3.60$-2.32$-2.63$-0.86$0.68$4.02
Low Forecast$-9.39$-7.28$-3.97$-2.70$-4.27$-3.28$-0.95$0.30
Surprise %19.73%7.03%5.05%14.29%----

Revenue Forecast

$0 $700M $1B $2B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$69.72M$77.65M$9.30M$221.90M----
Avg Forecast$78.26M$82.75M$12.29M$219.05M$176.98M$437.33M$967.67M$1.67B
High Forecast$170.79M$167.23M$16.09M$230.15M$313.43M$442.24M$1.01B$3.08B
Low Forecast$43.03M$43.07M$7.40M$214.98M$64.02M$432.43M$928.41M$588.98M
Surprise %-10.91%-6.16%-24.31%1.30%----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-639.30M$-493.96M$-643.20M$-535.76M----
Avg Forecast$-450.77M$-570.76M$-643.20M$-438.86M$-561.83M$-336.28M$-21.66M$311.59M
High Forecast$-360.62M$-456.61M$-514.56M$-376.93M$-428.14M$-139.25M$110.71M$654.37M
Low Forecast$-540.92M$-684.91M$-771.84M$-439.49M$-695.53M$-533.31M$-154.03M$49.48M
Surprise %41.82%-13.45%-22.08%----

BBIO Forecast FAQ

Is BridgeBio Pharma stock a buy?

BridgeBio Pharma stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 24 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BridgeBio Pharma is a favorable investment for most analysts.

What is BridgeBio Pharma's price target?

BridgeBio Pharma's price target, set by 25 Wall Street analysts, averages $88.8 over the next 12 months. The price target range spans from $69 at the low end to $100 at the high end, suggesting a potential 14.12% change from the previous closing price of $77.81.

How does BridgeBio Pharma stock forecast compare to its benchmarks?

BridgeBio Pharma's stock forecast shows a 14.12% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for BridgeBio Pharma over the past three months?

  • January 2026: 15.79% Strong Buy, 78.95% Buy, 5.26% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 16.67% Strong Buy, 77.78% Buy, 5.56% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 21.05% Strong Buy, 73.68% Buy, 5.26% Hold, 0% Sell, 0% Strong Sell.

What is BridgeBio Pharma’s EPS forecast?

BridgeBio Pharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.55, marking a 23.26% increase from the reported $-2.88 in 2024. Estimates for the following years are $-2.51 in 2026, $-0.57 in 2027, and $1.91 in 2028.

What is BridgeBio Pharma’s revenue forecast?

BridgeBio Pharma's average annual revenue forecast for its fiscal year ending in December 2025 is $176.98M, reflecting a -20.24% decrease from the reported $221.9M in 2024. The forecast for 2026 is $437.33M, followed by $967.67M for 2027, and $1.67B for 2028.

What is BridgeBio Pharma’s net income forecast?

BridgeBio Pharma's net income forecast for the fiscal year ending in December 2025 stands at $-562M, representing an 4.87% increase from the reported $-536M in 2024. Projections indicate $-336M in 2026, $-21.661M in 2027, and $311.59M in 2028.